Acumen Pharmaceuticals, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $225.2M | $122.2M |
| FY2022 | $0 | $188.8M | $130.1M |
| FY2023 | $29.9M | $267.0M | $66.9M |
| FY2024 | $29.4M | $181.8M | $35.6M |
| FY2025 | $22.4M | $70.4M | $54.0M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $225.2M | $122.2M |
| FY2022 | $0 | $188.8M | $130.1M |
| FY2023 | $29.9M | $267.0M | $66.9M |
| FY2024 | $29.4M | $181.8M | $35.6M |
| FY2025 | $22.4M | $70.4M | $54.0M |